Brunner AM, Esteve J, Porkka K, Knapper S, et al. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol 2024;99:E32-E36.
PMID: 37994196